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 List of abbreviations 
 
PD Parkinson’s Disease 
STN Subthalamic nucleus 
GP Globus pallidus 
GPi Internal Globus pallidus 
SN Substantia nigra 
SNr Reticular part of Substantia nigra 
SNc Compact part of Substantia nigra 
BDI Beck’s Depression Inventory 
MMSE Mini-Mental State Examination 
UPDRS Unified Parkinson’s Disease Rating Scale 
DBS Deep Brain Stimulation 
IPG Implanted Pulse Generator 
MRI Magnetic Resonance Imaging 
CT Computer Tomography 
PET Positron Emission Tomography 
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 Introduction  
What is Parkinson’s disease? 
Parkinson's disease (PD) is a progressive and chronic neurodegenerative disorder of           
the central nervous system. It is the second most common neurodegenerative disease            
and it affects 2-3% of the population that are above the age of 65 [poewe2017]. The                
etiology is unknown and no cure exists up to now, but some treatment options including               
medication and surgery are provided as to manage the symptoms of the disease. ​The              
pathogenetic mechanism of PD implicates the malfunction and eventually apoptosis of           
dopamine producing cells in the Substantia Nigra (SN). This has as a result the failure               
of the production of the neurotransmitter dopamine, which is essentially the chemical            
messenger that sends information to the parts of the brain that control movement and              
coordination. Thus, a patient with PD has decreased dopamine levels inside the brain,             
hence signals or messages are delivered to the motor-responsible areas erroneously,           
causing various motor or non-motor disorders to the affected patients. 
History of Parkinson’s disease 
Evidence for treatments of PD exist since early 5000 BC in the Indian medical practice,               
with no evidence when the disease was first "discovered". The first detailed medical             
essay on PD originates in 1817, a publication entitled "An Essay on the Shaking Palsy",               
written by the Medical doctor James Parkinson, in London, UK [parkinson2002]. The            
essay shone light on the disease and established it as a recognized medical condition.              
The research involved the observation of 6 subjects by James Parkinson. Three of them              
were his patients in his own medical practice in London and the remaining three were               
people that he observed in the streets. The symptoms of the disorder were clearly              
documented in the essay, which he described as "Involuntary tremulous motion, with            
lessened muscular power, in parts not in action and even when supported; with a              
propensity to bend the trunk forwards, and to pass from a walking to a running pace: the                 
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 senses and intellect being uninjured". Thus, three of the four main symptoms of the              
disease were described: tremors, rigidity and postural instability. He even theorized that            
the symptoms are caused by a problem in the medulla of the brain. The intention of the                 
essay was to encourage other people in the medical community to study this disease.              
But it was not until 60 years later that this essay attracted the attention it was supposed                 
to. Neurologist Jean Martin Charcot and colleagues distinguished the disease from           
other neurological disorders and truly recognized the significance of the condition and            
named it Parkinson's disease [goedert2017]. 
Epidemiology of Parkinson’s disease 
Epidemiological studies [tysnes2017] have as measures the incidence and the          
prevalence of PD. PD is the second most common neurodegenerative disorder, after            
Alzheimer's disease. It is estimated that 1 million patients in the USA are affected by the                
disease . World wide estimates vary from 15 patients in every 100000 people in China               
to 657 in 100000 in Argentina. This number is expected to increase threefold in the next                
50 years, as the lifetime of the population increases [tysnes2017]. 
The incidence describes the new cases of PD in a given time period. The measurement               
of incidence is very difficult as many patients may have had the disease but the               
symptoms have manifested clinically very slowly. The numbers vary from 1.5 in 100000             
in China to 20 in 100000 in US. 
Age is the most important factor affecting the onset of the disease. The incidence              
increases with age, however, the onset of the disease can appear at any age. The               
median age of onset is at 62.4 years for idiopathic PD and the cases for an onset before                  
the age of 40 is 10 %, with onset before the age of 30 being very rare. Prevalence also                   
increases with age. In the range of 50 - 90 years the prevalence is strongly increased. It                 
affects 0.3 % of general population of US and 3 % people older than 65 [tysnes2017]. 
The disease is present worldwide, in all populations and is found to be more common in                
populations in Europe and North America (100-350 in 100000). It is assumed to be              
more prevalent in the Caucasian race. It is generally one-fifth or one-tenth common in              
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 African-American or Asian populations. Recent studies have come to the conclusion           
that environmental factors are more important than racial ones, as it was found that the               
prevalence was the same in African-American populations and White populations living           
in the same geographical area [tysnes2017]. 
Etiology of Parkinson's disease 
The combination of both environmental and genetic factors is considered to be strongly             
linked with the development of PD, however there cause is still unknown. There are              
many hypotheses surrounding the topic: free radicals, accelerated aging, environmental          
toxins and genetic predisposition are some probable pathogenetic factors. The single           
biggest risk factor of PD is advancing age, with men having a slightly elevated risk than                
women. Family history also plays an important role, since people with an affected             
first-degree relative have a double risk for developing the disease. Caffeine           
consumption and cigarette smoking are reported to present a reduced risk of developing             
PD, but they are not recommended as strategies to avoid PD, and also the negative               
impact of smoking in general health is enormous compared to the slight possible             
reduction in risk of developing PD [tysnes2017]. 
Physical trauma, exposure to chemicals and infections, as well as nutrition are factors             
that are believed to affect the developing of PD. Consistent findings show that rural              
living, agricultural work and exposure to well water increase the risk to develop PD.              
Hence, pesticides and herbicides may contribute to the disease [tysnes2017].          
Environmental toxins, such as MPTP can cause the same symptoms to animal models             
as PD. 
Studies in 2005 [klein2012, brice2005] found that a single mutation in the gene LRRK2              
represents an important fraction of PD. Further studies are being conducted to discover             
the relation between genes and PD. A very recent study, released in the beginning of               
2009 [gitler2009] found a connection between genetic and environmental causes of PD.            
A genetic interaction was found between two Parkinson's disease genes, namely the            
alpha-synclein and PARK9. Through their research, they determined that the PARK9           
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 protein can protect cells from manganese poisoning, that is a significant environmental            
risk factor for developing PD. It is prevalent in occupations such as mining, welding and               
steel manufacturing. Excessive exposure to manganese causes the manganese to          
attack the nervous system producing motor symptoms. The alpha-synuclein protein that           
is normally found in brain is then forced to misfold and form clumps. 
Pathophysiology of Parkinson's disease 
The neurophysiologic cause, in accordance to the main neuropathologic findings​, in PD             
is the failure of the responsible cells in the brain to produce the substance dopamine.               
The production of dopamine occurs prominently by the dopaminergic neurons in the            
midbrain, more specifically in SN. SN belongs to a group of brain structures, namely the               
basal ganglia that is innervated by the dopaminergic system and is considered to be the               
main location inside the brain that is affected by the disease. 
Physiology 
Basal Ganglia (Figure 1) is a group of nuclei that are present in the brains of                
vertebrates. The main components are the SN, subthalamic nucleus (STN), globus           
pallidus (Gi) and striatum (which consists of the caudate nucleus and putamen). The             
basal ganglia are responsible for a variety of functions, such as motor control and              
learning. Experimental studies show that they exert an inhibitory influence on a number             
of motor systems [purves2012]. The release of this inhibition gives rise to the activation              
of the corresponding motor system. 
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Figure 1. The human brain as viewed from the side, showing the position of the basal                
ganglia [nieuwenhuys1981].  
 
Figure 1 shows the flow of the neural signals within the basal ganglia. The striatum is                
the largest component of the basal ganglia and is the main recipient of signals from               
brain areas external to the basal ganglia, such as the cerebral cortex. The reticular part               
of the substantia nigra (SNr) and the internal segment of the globus pallidus (GPi) are               
the primary sources of output signal, with the majority resulting in the thalamus. The              
striatum then projects directly and indirectly (via STN) to GPi and SNr. Substantia nigra              
consists of two parts: SNr and the compact part (SNc). The former functions similarly to               
the globus pallidus, while the compact part sends modulatory dopaminergic input back            
to the striatum and other structures. 
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  There are three key pathways within the basal ganglia (Figure 2): First, the direct              
pathway which has two GABAergic inhibitory links in a row (Striatum through GPi/SNr to              
Thalamus) so that activation of the striatum disinhibits or releases the motor thalamus.             
Second, the indirect pathway that works in opposition to the direct one, in the sense that                
the added link through the STN excites the direct pathway inhibitory function. Third is              
the striatonigral pathway to the SNc which forms a loop with the dopamine-containing             
nigrostriatal pathway which degenerates in PD. 
 
Figure 2. Neuronal pathway in a normal brain. 
 
This system of nuclei, neurons, neurotransmitters constructs a complicated         
communication network. Dopamine is the chemical neurotransmitter that its lack inside           
the brain leads to PD. Dopamine is created in SN and helps with the transmission of                
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 messages to the striatum, which initiates and control the movement and balance. The             
proper dopamine messages help the muscles of the body to operate smoothly and to be               
precisely controlled [galvan2008]. When a dopamine message is required, SNr gathers           
a cluster of dopamine particles at the end of the nerve cell until it releases it to the                  
synapse. A neighbouring nerve cell collects this dopamine particles into pockets. This            
process is called stimulation. The neighbouring cell will now perform the same            
procedure as to concentrate its own dopamine particles into clusters and hence            
stimulate further nerve cells to pass the signal [galvan2008]. An important step in this              
procedure, is that the receiving cell breaks the used and the excess (that may not fitted                
into a pocket) dopamine particles into MAO-B. This break down of the dopamine             
particles is crucial to the fine tuning of both coordination and movement. 
Pathology 
In PD, the cells in SNr responsible for the production of dopamine start to decrease in                
number. As a result, the dopamine production decreases and hence the amount of             
available dopamine falls down. The enzyme MAO-B also continues to deplete any            
dopamine that is present in the synapse. In terms of the circuits mentioned above, the               
nigrostriatal dopaminergic projection originating in SNr degenerates and leads to a           
striatal dopaminergic deficit. This circuit would normally modulate the excitatory          
influence of the cortical afferents on the striatal projection neurons. This dopamine            
deficiency leads through a cascade of activity changes to an increased neuronal activity             
of the STN and conversely of the GPi/SNr as the two pathways that performed inhibitory               
effect stop working properly. As a result of this pathway disruption, the smooth             
operation of muscles is consequently prevented. 
Symptoms of Parkinson’s disease 
Motor symptoms 
The cardinal symptoms of PD are manifested as motoric signs. They develop due to the               
fact that the function of the areas of the brain that control motoric movement and               
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 coordination fail to work normally due to the lack of sufficient levels of dopamine in the                
corresponding centers as explained earlier . The most common of the motor symptoms             
are: tremor, rigidity, gait/postural instability, bradykinesia and akinesia [goetz2008]. 
Bradykinesia is the most characteristic clinical feature of PD. It manifests itself with slow              
movements. It includes various levels of voluntary movement such as planning, initiation            
and execution - the performance of sequential and simultaneous tasks are also            
affected. The symptom initially manifests itself as general slow movement and slow            
reaction times in daily life. Most of the times these include difficulties in performing tasks               
that require fine motor control, e.g., buttoning, using utensils etc. Further manifestations            
include loss of spontaneous movements and gesturing, drooling (due to impaired           
swallowing) monotonic and hypophonic dysarthria, loss of facial expression, or most           
commonly "masking", decreased blinking and reduced arm swing while walking. The           
later stage of bradykinesia is akinesia, in which the patients essentially lose their ability              
to move. Micrographia is also one of the manifestations of bradykinesia and is a result               
of the decreased amplitude in movement and it points out the alteration of the life of the                 
patients by showing their reduced ability to write in a good and recognizable fashion, as               
their handwriting becomes small and cramped. 
Tremor is mainly distinguished as rest, action and postural tremor. Rest tremor is the              
main tremor evident in PD and is also one of the most common symptoms in PD and -                  
like bradykinesia - is also very easily recognizable. It occurs when a body part is               
completely rest against gravity. The tremors occur unilateral with a frequency of 4 - 8 Hz                
and most often occur at the distant part of the limp. They tend to spread from one hand                  
to the other and can also involve the tremor of the lips, chin, jaw and legs but rarely the                   
head or voice. Rest tremor characteristically disappears with voluntary action and sleep.            
Postural tremor occurs when the patient assumes a horizontal outstretch position, i.e., a             
position against gravity. This tremor increases with voluntary action, as opposed to rest             
tremor, which decreases with movement. The last and least of tremor categories is the              
action tremor (or kinetic) which occurs during voluntary movement. The tremor of early             
PD is most often intermittent, and may not be noticeable to others. In fact, about half of                 
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 patients with PD report a sensation of internal tremulousness in the limbs or body that is                
unrelated to the presence of observable tremor [shulman1996]. However, as the           
disease progresses, tremor usually becomes evident. 
Rigidity arises due to stiffness in the joints and increased muscle tone. Rigidity             
combined to an underlying tremor are evident as a passive movement of the limb              
(flexion, extension or rotation about a joint). It can occur at the neck, shoulders, hips or                
at the wrists and ankles. Voluntary movements of the contralateral limb usually increase             
rigidity and for that reason are useful in diagnosing the symptom. Rigidity is often              
associated with pain - painful shoulder is one of the most frequent manifestations of PD.               
Rigidity of the neck and trunk result in conditions such anterocollis or scoliosis and              
postural deformities can occur due to this symptom. Other skeletal abnormalities that            
may occur due to rigidity are extreme neck flexion (dropped head, bent spine) and              
truncal flexion (camptocormia). 
Postural instability is in general a late manifestation of PD and it most commonly has a                
late onset. It occurs due to loss of postural reflexes and it is the most common cause of                  
falls causing usually hip fractures. 
Another form of akinesia (loss of movement) is freezing, or motor blocks. This is a very                
common and evident symptom of PD. It most commonly affects the legs while moving,              
but can also affect the arms and eyelids. It manifests as sudden and transient inability to                
move and is also a very common cause of fall. There are five subtypes of freezing: start                 
hesitation (hesitation when beginning to walk), turn hesitation, hesitation in tight           
quarters, destination hesitation and open space hesitation. 
Parkinsonian gait is a distinctive unsteady walk. The parkinsonian patients tend to lean             
backward or forward in an unnatural fashion and develop a stooped, head-down,            
shoulders-dropped stance. The walking tends to occur in small shuffling steps, a            
symptom of PD called festination. 
Dystonia is a neurological movement disorder, occasionally appearing as a symptom of            
PD. It appears as sustained muscle contractions which cause twisting and repetitive            
movements or abnormal postures. 
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 Bulbar dysfunction can be manifested by dysarthria, hypophonia, dysphagia,         
sialorrhoea. These symptoms can sometimes be more crucial than tremor and akinesia            
as they can be more disabling. Speech disorders such as monotonous, soft and breathy              
speech with variable rate and difficulty of finding the correct words are also usual              
manifestations. Dysphagia owes its onset in the gradual inability to swallow or by             
prolongation of laryngeal or oesophageal movement. 
Parkinsonian patients can also experience respiratory disturbances, and these can of           
restrictive or obstructive nature. The obstructive pattern is usually related to rigidity,            
cervical arthrosis or restricted range of motion in the neck. The restrictive pattern may              
be related to chest wall rigidity. 
All the motor problems of the parkinsonian patient result to significant problems in the              
patient's daily life. Problems arise in otherwise routine everyday activities, such as            
talking, walking, writing, wearing clothes, cutting food, feeding, performing the common           
hygiene actions, driving, arising from a chair, turning in bed. This list is very long,               
underlying the difficulties of these patients to perform the most simple everyday actions. 
The progression of the disease is unpredictable and the speed and severity of the              
symptoms vary for each person. 
Non-motor symptoms 
The non motor symptoms of PD include cognitive and neurological disorders, autonomic            
dysfunction, sensory and sleep difficulties. Features of autonomic dysfunction include          
orthostatic hypotension, sweating dysfunction, sphincter dysfunction and erectile        
dysfunction. 
Neurological disorders are depression, apathy, dementia, anxiety and hallucinations.         
Patients may exhibit obsessive-compulsive and/or impulsive behavior e.g., craving,         
binge eating, compulsive foraging, hypersexuality and pathological gambling. 
Sleep disturbances may arise due to nocturnal tremors, physical discomfort related to            
stiffness or rigidity, inability to roll over in bed, bladder problems, restlessness and             
painful dystonia. A common experience in patient is vivid dreams and hallucinations,            
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 acting out violent nightmares. This problem is called "REM sleep disorder". Another            
common problem is the "sleep-wake reversal pattern" in which there is a tendency of              
sleeping too much during a day and then developing insomnia at night.  
Restless leg syndrome is also very common to produce sleep disorders due to the              
irresistible urge to move one's body, as to stop uncomfortable sensations. 
Sensory symptoms such as olfactory dysfunction, pain, paresthesia, akathisia, oral pain           
and genital pain are frequent but are often not recognised as parkinsonian symptoms. 
Fluctuations 
Motor fluctuations occur very commonly to patients having PD. They are characterized            
by frequent switches in the patients between "on" and "off" periods, meaning periods             
that the patient may react good to the medication and periods that still experiences the               
symptoms of PD. 
Diagnosis of Parkinson’s disease 
There is no standardized method for diagnosing PD so far. The diagnosis is mainly              
based on clinical impression, with no physiologic or blood tests for confirming the             
diagnosis. The common way of providing a diagnosis for the disease is through clinical              
neuropathologic examination. It is generally accepted that bradykinesia, plus tremor or           
rigidity are the necessary symptoms for diagnosing idiopathic PD. The good response to             
dopaminergic therapy is an important criterion for the diagnosis. 
Neurodiagnostic imaging techniques such as conventional MRI and CT-scan are          
insufficient for providing a diagnosis for PD while Positron Emission Tomography (PET)            
and Single Photon Emission Computed Tomography (SPECT) may be useful in           
providing an early diagnosis for PD [martinwieler2008). 
Another test showing whether a patient has Parkinson's disease, is using the Unified             
Parkinson’s Disease Rating Scale (UPDRS), which is explained in "Methods" chapter.           
The patients are given a dose of levodopa (e.g., carbidopa-levodopa 25/250 mg) or             
subcutaneous apomorphine (1.5 to 4.5 mg). If the UPDRS score is significantly            
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 improved 20 minutes to one hour after the administration of levodopa or apomorphine,             
this provides a sign that the patient has the disease. 
Medical treatment of Parkinson’s disease 
Handling of the symptoms through medications, surgery or both is used at present to              
ease the quality of life of PD patients. Levodopa, COMT inhibitors, dopamine agonists             
and MAO-B inhibitors [oertel1997] are the main groups of medications that are used to              
control the motor symptoms. 
There are two phases that usually separate the progression of PD. The first phase              
usually relates to the development of a disability. Pharmacological treatment is then            
used in order to relieve the symptoms. The second phase relates to the development of               
complications due to the continuous administration of levodopa. In the first phase the             
aim is the equilibrium between reduced dopaminergic therapy and good management of            
symptoms. MAO-B inhibitors and dopamine agonists are usually administered before          
the levodopa (or L-dopa) in order to delay the L-dopa related complications. Gradually,             
medication stops controlling the symptoms and deep brain stimulation (or some other            
form of surgery) are used as last resorts. 
Levodopa 
Levodopa is a precursor of the neurotransmitter dopamine and works by replacing            
dopamine when the brain cells in the SN are no longer able to produce if an individual                 
has the PD. Levodopa can cross the blood brain barrier, in contrast to dopamine that               
can not. Hence, despite the fact that dopamine was first synthesized in a laboratory in               
1910, in London, UK by George Barger and James Ewens only 50 years later, levodopa               
was synthesized and could actually be used for treatment of Parkinson’s disease            
[fahn2008]. Hornykiewicz, after measuring the levels of dopamine in people with PD            
published a monumental paper on the depletion of dopamine in the caudate and             
putamen nuclei of patients with both of these conditions, but not in patients with other               
brain disorders such as Huntington​s chorea [hornykiewicz1998]. Later, Hornykiewicz         
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 [hornykiewicz2008] published a major review article positing that striatal dopamine          
deficiency is correlated with most of the motor symptoms of PD. 
Over the next years the dopamine pathways in the brain were mapped and the              
nigrostriatal pathway was discovered. Also the dopamine in the nigra of animals was             
found to be reduced when the nigra was injured. 
The treatment with L-dopa began in 1960, when intravenous injections of the drug to              
patients having PD produced significant but transient effects in the patients. In the             
coming years, treatments with L-dopa produced contradictory effects to patients and           
doctors began questioning its effect. 
The patients experienced nausea and vomiting and could not tolerate high doses of the              
levodopa since only 5-10 percent of the drug crosses the blood-brain barrier while the              
remainder metabolizes to dopamine elsewhere, causing the adverse events. In 1967, a            
new technique for administering the drug, produced by George Cotzias removed these            
undesirable effects. The key was to administer the drug gradually. This diminished the             
gastrointestinal side effects. In the following years, the benefit of levodopa to PD             
patients was verified with various studies [fahn2008]. 
Nowadays, dopa decarboxylase inhibitors are used in combination with levodopa in           
order to help prevent the metabolism of L-Dopa before reaching the dopaminergic            
neurons. Such combinations are carbidopa/levodopa (e.g., Nacom) and        
benserazide/levodopa (e.g., Madopar). 
Despite the dramatic benefit on treating patients with levodopa, the drug has also             
weaknesses. A lot of patients start having their symptoms reemerging during the day             
after being treated for half year. Many patients also develop dyskinesias. Motor            
fluctuations and psychiatric symptoms start to appear as well. As a fact, levodopa             
reduces effectively the cardinal symptoms of PD, often for long periods of time, hence              
the quality of the daily lives of patients are improved to a major extent. Chronic               
levodopa treatment causes complications to patients (such as levodopa induced          
dyskinesias) and finally the use of the drug results no effect. Furthermore many of the               
symptoms that do not respond to L-dopa treatment, such as non-motor symptoms,            
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 speech difficulties and cognitive decline are the symptoms that are most disabling in             
PD. Thus, although treatment with levodopa is the most effective symptomatic           
treatment, the developing of dyskinesias and also the decision on whether to start early              
or late treatment need to be addressed.  
COMT inhibitors 
COMT inhibitors are drugs that inhibit the action of catechol-O-methyltransferase​, an           
enzyme involved in degrading neurotransmitters. The drugs are used in combination           
with levodopa for the treatment of PD. Entacapone is a commonly used COMT inhibitor.              
Entacapone combined with carbidopa and levodopa are commercially found under the           
trade name Stalevo. COMT inhibitors are important if the patients have “on”/”off”            
fluctuations, as it increases the “on” period. In addition COMT inhibitors prolong the             
effect of levodopa, reducing the pulsatile dopamine receptor stimulation and thus           
contribute to delaying the appearance of fluctuations during the course of the disease. 
Dopamine agonists 
Dopamine agonists bind to dopaminergic post-synaptic receptors. Hence they have a           
similar effect to levodopa. It was originally used as a complementary therapy to             
levodopa, reducing the on/off fluctuations and dyskinesias. They are finally used on            
their own as an initial therapy and as a way to delay the motor symptoms and avoid the                  
motor complications caused by levodopa treatment. When used in later stages, they            
are effective in reducing the off periods. Dopamine agonists include pramipexole,           
ropinirole, pergolide, bromocriptine, apomorphine and others. 
They produce mild side effects, such as nausea, constipation, hallucinations, insomnia.           
But, they can control worse symptoms than levodopa in the early stages, while delaying              
the motor complications so they are preferred from levodopa as an earlier treatment. At              
higher doses they are related to a variety of impulse control disorders. 
Apomorphine is one of the most commonly used dopamine agonists. It is non-orally             
administered and may be used to reduce off periods and dyskinesia in late PD. It is                
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 administered by intermittent injections or continuous subcutaneous infusions with side          
effects being among others confusion and hallucinations. 
MAO-B inhibitors 
MAO-B inhibitors (selegiline and rasagiline) block the metabolization of dopamine in the            
basal ganglia, leading to increased amount of neurotransmitter. Thus, reducing the           
MAO-B results in higher quantities of levodopa in the striatum. They improve motor             
symptoms and delay the need for levodopa treatment. Efficiency in later stages of the              
disease is reduced. The MAO-B inhibitors have potential neuroprotective effect          
[mandel2005] and this is the main reason they are prescribed, rather than symptomatic             
effects that are poor compared to other medication. 
Deep brain stimulation 
The practice of surgery for psychological or neurological disorders has long been            
present in medicine. The famous lobotomies of 40s and 50s are examples of such              
techniques that promised treatment to the patient. Ablative brain surgeries, which are            
the surgical ablations by burning or freezing brain tissue were used to treat such kind of                
disorders. These ablative techniques started declining due to the high morbidity and            
various post surgical complications. After the development of levodopa-based         
treatment, the operation of ablative surgeries further declined. But observations of           
various adverse events due to the continuous administration of levodopa lead the            
researchers back to the search for new surgical treatments as to avoid medication, and              
Deep Brain Stimulation (DBS) evolved as a solution for this. 
DBS started in France, in 1987 [benabid1987]. The first reports of DBS being used to               
treat PD was in 1993 [pollak1993]. As an official treatment of Parkinson's disease, DBS              
was adopted in early 2000. A rough estimate of the patients being treated with DBS               
worldwide, gives a number of about 75000 people. The new technique is minimally             
invasive and does not destroy the brain tissue, but sends electrical pulses with             
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 electrodes that are implanted in the regions that are believed to cause PD (Figure 3               
shows a typical DBS system). 
There are various factors making DBS attractive for PD treatment: (1) no destruction of              
brain tissues needed, (2) it is reversible in the sense that it does not preclude the use of                  
future treatments, (3) stimulation parameters can be tuned post operatively as to            
improve efficacy and reduce any side effects that might develop, (4) in contrast to              
ablative procedures, it can be safely performed bilaterally. Furthermore, performing the           
surgery leads to reduced administration of levodopa hence the levodopa induced           
complications, e.g., dyskinesias, are also reduced [breit2004]. 
 
 
Figure 3. Typical Deep Brain Stimulation system [rosa2012]. 
Target brain regions for DBS 
Experimental studies [blesa2012] using animal models underlined the effects of nigral           
degeneration and dopamine deficiency in Parkinson's disease and their role in the            
disruption of the normal operation of the according neural pathways. This irregular            
operation of the pathways include: (a) the excessive STN excitation of the GPi and (b)               
excessive GP inhibition of the thalamus. 
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 These studies made clear that the regions in the brain that play a significant role in the                 
cause of PD are STN and GPi. So extensive experimental work was conducted as to               
accurately specify these regions inside the brain and stimulate them, as to restore these              
nuclei to their normal function. This technique is highly region specific, so precise sites              
for conduction of DBS are important to be known. 
 
Figure 4. Basic (left) and extended (right) basal ganglia-thalamocortical circuitries          
under normal conditions [breit2004]. 
 
Figure 4 shows the basic and extended basal ganglia-thalamocortical circuitries under           
normal conditions. The motor circuit connects the motor cortical areas and the primary             
somatosensory cortical areas with the dorsolateral putamen. The dopamine deficiency          
in the parkinsonian state lead over a cascade of activity changes to an increased              
neuronal activity in STN and GPi-SNr. High frequency stimulation in these areas leads             
to inhibition of the neuronal activity, leading to improvement of PD symptoms, with the              
effect being always reversible. 
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Figure 5. Stimulating electrodes located in the subthalamic nucleus (STN) and in            
globus pallidus GP (Source: www.wikipedia.org). 
 
STN is the region being mostly used - and also used in this thesis - because it reduces                  
the cardinal motor symptoms of PD maximally, more than any other target region up to               
date [deuschl2006]. It also leads to reduced need for administration of levodopa (in             
contrary to stimulating the GPi which is not associated with reduction of levodopa             
requirement) in parallel to the conduction of DBS and is one of the main advantages of                
performing the surgery, since levodopa induced dyskinesias are also reduced. Figure 5            
shows the position of the STN and GPi in the brain, together with the location of the                 
electrodes providing the neurostimulation. 
DBS system and procedures 
The DBS system consists of three components: the implanted pulse generator (IPG),            
the lead, and the extension. The IPG is a battery-powered neurostimulator encased in a              
titanium housing, which sends electric pulses to the brain to interfere with neural activity              
at the target site. Such neurostimulators are Activa PC neurostimulator (Medtronic) and            
Kinetra (Medtronic). These devices can provide bilateral stimulation. The lead is a coiled             
wire insulated in polyurethane with four platinum iridium electrodes and is placed in one              
of three areas of the brain. The lead is connected to the IPG by the extension, an                 
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 insulated wire that runs from the head, down the side of the neck, behind the ear to the                  
IPG, which is placed subcutaneously below the clavicle or in some cases, the abdomen. 
The accurate implantation of the electrodes in the established regions inside the brain is              
essential. Imaging techniques such as MRI, CT and ventriculography are used for            
pre-operational targeting. The implantation of electrodes is done by a stereotactic           
procedure while the patient is not being anaesthetized, but awake, with the patient             
being with no medication for about 12h before the operation. 
An electrophysiological exploration is needed before the implantation of the final           
electrodes. This exploration is divided into two steps: (1) micro-recordings and (2)            
test-simulation. The first step, the micro-recordings, are performed to identify specific           
firing patterns along traversed brain regions. It is mainly used to identify the STN              
borders. The patient is subject to the increased risk of hitting a blood vessel, an               
increased operation time and sometimes the possibility of gaining very limited           
information. However, it leads to increased confidence and in correct target localization            
due to refined target region characterization. 
Test simulation is an intraoperative stimulation at various sites along the trajectory. This             
is done to access if there is any symptomatic improvement occurred such as             
suppression of rigidity and tremor. Another reason for conduction of test stimulation is to              
detect any threshold above which side effects are induced due to current spreading in              
adjacent brain structures. The stimulation electrode can provide monopolar or bipolar           
stimulation and t has four sites by which stimulation can be achieved. Bipolar             
stimulation is achieved by having two contacts along the electrode active, one being the              
positive pole and one the negative, while for monopolar stimulation, the case of the              
stimulator is positive and one of the contacts negative (Figure 6). Monopolar stimulation             
produces a current in which the electrons diffuse from one site which is negatively              
charged through the brain. This stimulation might affect a larger area, especially if the              
current density is high. Concentric bipolar stimulation produces a concentrated current           
in which current runs from the negative to the positive pole. 
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Figure 6. Monopolar and bipolar stimulation. For monopolar stimulation, one of the 4             
contacts is negative, with the case being positive. For bipolar stimulation, one of the 4               
contacts is positive and one negative. 
 
Post operative localization of stimulation of most effective contacts within the STN have             
showed that the most effective site is the anterodorsal part of STN [breit2004]. 
The stimulation parameters used are 120 - 180 Hz frequency of stimulation, 60 - 200 μs                
pulse width and 1 - 5 V stimulation amplitude for treatment of tremors, and 20 Hz for the                  
treatment of dyskinesias. A problem occurs to patients showing symptoms of tremor            
and dyskinesias as well. In that case a compromise in the frequency has to be found. 
Bilateral DBS of STN might improve the UPDRS scale in off period by 50% - 90%                
describing a major improvement of the symptoms. Most features are improved if            
patients responded well beforehand with levodopa treatment. 
Preoperative levodopa response of the patient is a strong and robust predictor of             
postsurgical improvement after DBS of the STN [louis2001]. In almost all cases, the             
outcome of the surgery can be as good as the best preoperative levodopa response.              
This means that all the symptoms that do not response to levodopa treatment are              
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 unlikely to improve following the surgery. But this does not alter the need for use of                
DBS. In a lot of cases the levodopa treatment is being limited due to various adverse                
events. Hence, DBS of STN will probably produce a better response to the             
subtherapeutic levodopa dosage. 
The mechanisms that cause symptoms improvement induced by DBS are not fully            
understood. It is evident that the frequency of stimulation is a key factor to the success                
and that high frequency stimulation effectively and interestingly mimics the effects of            
ablation in various brain structures. There are various hypotheses that are investigated            
and are the candidate explanations for the success of DBS, though there is no crucial               
evidence pointing directly to any of them [mcintyre2004]. 
Adverse events 
Adverse events are typically related to factors as : (1) surgery, (2) hardware failure, (3)               
stimulation problems. Unmet expectations, problems with social adaptation after         
dramatic improvement of motor functions are also secondary adverse effects. Two           
studies [umemura2003, oh2002] with a total of 360 patients (288 with PD), that had              
DBS showed that within one month of the procedure, 0.6 percent resulted to death and               
permanent neurologic complications to 2.8 percent. Infections was at 5.6 percent,           
hemorrhage in 3.1 percent of the patients confusion/disorientation in 2.8 percent,           
seizures in 1.1 percent. Other complications that were below one percent are not             
mentioned. A systematic review in 2006, that included 29 studies of STN DBS with 778               
patients [kleinerfisman2006] showed the following results: transient confusion and         
intracerebral hemorrhage were the most common adverse events (15.6 and 3.9 percent            
respectively). Infections were present in 1.7 percent of patients and seizures in 1.5             
percent. The percentage of death cases was minimal. Both of these group studies             
elucidate the fact that complications and adverse events in STN DBS are present, but              
serious adverse events (leading to death or neurological problems) are very uncommon. 
In the same studies, the hardware complications were also reviewed. Lead replacement            
due to fracture, migration or malfunction, lead repositioning due to misplacement,           
extension wire replacement due to fracture or erosion, IPG replacement due to            
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 malfunction, allergic reaction to the hardware were some of the complications that            
existed. A systematic review [kleinerfisman2006] showed the same variety of hardware           
complications. The rapid development of DBS technology constantly leads to the           
reduction of such complications. 
Neurostimulation related problems included paresthesia, dysarthria, eyelid opening        
apraxia, hemiballismus, dizziness, dyskinesia and facial contractions. These were         
results from the same group of four studies. These problems were in general mild and               
could easily be resolved with proper adjustment of the stimulation parameters. The most             
common adverse events induced by the stimulation were dysarthria, gain weight,           
depression and eyelid opening apraxia [kleinerfisman2006].  
Purpose of the study 
The primary purpose of this retrospective, unblinded and long-term study is to assess             
the efficacy and safety of bilateral DBS of STN in a set of parkinsonian patients that                
respond well to levodopa treatment using review of patient records. The cohort of             
patients in this study is not pre-selected, but it includes subsequent patients eligible for              
DBS surgery. Several patients were excluded from the study for objective reasons. A             
set of measures, primarily UPDRS, was used to characterize the efficacy of the             
treatment, and the adverse events were monitored in order to assess the safety. The              
study was conducted in a single clinical center in Tübingen, Germany.  
Methods 
Patients   
The inclusion criteria for the patients in the study were clinically diagnosed idiopathic             
Parkinson’s disease [hughes1992], disease duration longer than 5 years, age between           
25 and 80 years, UPDRS score ​≥ ​30 in medication “off” condition, a stable medication               
Parkinson treatment for at least one months before surgery and written informed            
consent. 
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 The exclusion criteria were strong depression (Beck’s Depression Inventory > 25),           
cognitive impairment (Mini-Mental State Examination < 25), acute psychosis, surgical          
contraindications, severe internal diseases, e.g., immunodeficiency, non-curative       
malignant diseases, severe neurological disorders (epilepsy, brain surgery, brain         
trauma, brain infarction), previous treatment with DBS or lesion of basal ganglia nuclei,             
lack of consent or existing care, lack of ability to understand the purpose and course of                
the study and participation in other clinical trials. 
Procedure 
Deep brain stimulation 
All patients received bilateral implantation of electrode leads in the STN. After the             
surgery following stimulation parameters are set and optimized by a trained movement            
disorders specialist in order to obtain optimal clinical results and avoiding side effects:             
(1) stimulated contact(s), (2) stimulation type (monopolar or bipolar stimulation), (3)           
stimulation amplitude, (4) stimulation frequency, (5) pulse width of stimulation. Over the            
time, taking into account the evolution of the symptoms and the course of the disease,               
further optimization of the stimulation parameters might be necessary. 
Patient visits 
The clinical assessment was performed for each patient at baseline (before surgery)            
and at one, two, three and four years after surgery during the regular inpatient stays and                
the following measures have been assessed: UPDRS, Beck Depression Inventory          
(BDI), Mini-Mental State Examination (MMSE), Dysphagia, Dysarthria, adverse events,         
medication and stimulation. 
Outcome measures 
Unified Parkinson's Disease Rating Scale (UPDRS) 
The most common way to assess the variety and severity of problems endured by a               
patient with PD is through the use of the UPDRS. The aim of this scale is to provide a                   
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 comprehensive evaluation of the disability and impairment related to the PD           
[goetz2008]. ​The UPDRS was originally developed in the 1980s and since then it has              
become the standard clinical rating scale for Parkinson’s disease. For clinical trials            
assessing new treatments for PD, the UPDRS scale has been used to determine the              
treatment related benefits. Its adaptation as the standard clinical rating scale for PD is              
due to its several strengths, including its wide utilization, its application across the             
clinical spectrum of PD, its nearly comprehensive coverage of motor symptoms, and its             
clinimetric properties, including reliability and validity.  
One of the core advantages of this rating scale, compared to some previous ones, is               
that it was developed to capture multiple aspects of PD. It has four subscales/sections              
complemented with the modified Hoehn and Yahr staging (part 5) and the Schwab and              
England ADL (part 6) scales. Section I assesses non-motor activities of daily living,             
namely mentation, behavior and mood. The scores are taken by interview and are             
based on the patients’ experiences and consists of 4 items that get a score between 0                
(normal) to 4 (severe) with 16 points being the maximum. Section II assesses motor              
activities of daily living for both “medication on” and “medication off” conditions. It             
contains 13 items that get a score between 0 (normal) and 4 (severe) with maximum               
score 52 points and as with section I, the scores are taken by interview. Section III is the                  
most interesting subscale of UPDRS as it contains the motor examination taken by a              
specialized physician at scheduled visits of the patients at the examination centers. It             
contains 14 items that can result in 23 scores as different sides and body parts are                
separately evaluated. The maximum score is 108. This section is evaluated in            
medication “on” and “off” conditions combined with stimulation “on” and “off” conditions.            
Furthermore the items in sections III can be grouped together in order to provide              
separate scores for the categories: a) gait, b) tremor, c) rigidity, d) akinesia. Section IV               
assesses the complications of the treatment and they are taken by a specialized             
physician as well. It contains 11 items and the scoring is irregular compared to sections               
I - III. The scores for the items can take the values 0 to 4 and 0 or 1 and the maximum                      
score is 23 points. The maximum score for UPDRS I-IV is thus 199 points. 
  
30 
 The modified Hoehn and Yahr staging (UPDRS V) scale is used to describe the              
symptom progression of Parkinson’s disease. It has 7 stages: 0 to 5 and in addition 1.5                
and 2.5. Stage 0 indicates no sign of the disease and stage 5 indicates wheelchair               
bound or bedridden unless aided. 
The Schwab and England ADL scale (UPDRS VI) measures a person’s ability to             
perform everyday life activities in terms of speed and independence. It has 10 scores in               
terms of percentages with 0% indicating vegetative functions such as swallowing and            
100% completely independent with ability to all activities without slowness, difficulty or            
impairment. In this study, the UPDRS VI scores are not taken into account due to the                
lack of sufficient results. 
L-Dopa test 
The severity of motor Parkinson's symptoms (UPDRS III) is evaluated using the L-Dopa             
test. The assessment of the UPDRS III score on the medication “off” condition started in               
the early morning after stopping L-Dopa and COMT inhibitors overnight (at least 12             
hours). All dopamine agonists other than cabergoline were discontinued at least 24            
hours before the test. Patients with cabergoline were switched to other drugs at least 1               
week before the test. The dwell time in the med "off" state was a few hours and may be                   
accompanied by an impairment of motor function or the occurrence of tremor. Patients             
did not receive their first morning dopaminergic drug dose as usual immediately after             
getting up, but only after completion of the examination in the med "off" state, i.e., with a                 
delay of a few hours. The L-Dopa dose for the test was 1.5 to 2 times the individual                  
L-Dopa equivalent dose in the morning. For later evaluations, the same dose should be              
used pre- and postoperatively. Clinical evaluation of the UPDRS III score in the             
medication "on" state was performed at a time interval with the best therapeutic effect.              
For this, the symptoms should be stable for at least 10 minutes and both the patient and                 
the investigator agreed that the best medication "on" condition of the patient has been              
achieved. 
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 Mini-Mental State examination (MMSE) 
The MMSE is a 30 point questionnaire that is used regularly in clinical trials in order to                 
measure cognitive impairment. It is used to screen for dementia. Though it is best suited               
for Alzheimer’s disease, it has been widely used for screening patients with PD             
[folstein1975]. 
Dysphagia 
Dysphagia can be defined as inefficient or unsafe transfer of food, liquid or saliva from               
the mouth into the stomach [tjaden2008]. Complications of this disorder include           
aspiration pneumonia, malnutrition, and dehydration. The first complication, aspiration         
pneumonia, is one of the major causes of death in PD. Hence, early identification and               
management of swallowing abnormalities is crucial for reducing the likelihood of these            
complications that negatively impact health status and quality of life [tjaden2008]. 
Dysarthria 
Damage in the central of peripheral nervous system can cause the disorder of             
dysarthria. The major manifestation of dysarthria is spoken communication and is           
associated with a loss in the muscular control that is relevant for speech. Reduced              
comprehensibility is arguably the most significant functional limitation of dysarthria, with           
voice and speaking rate being also limitations that affect a person’s ability to             
communicate in a normal way [tjaden2008]. 
Beck Depression Inventory (BDI) 
BDI is a 21 question multiple-choice self-report inventory that is one of the most              
frequently used psychometric tests for measuring the severity of depression [beck1961]. 
Adverse events 
Adverse events related to the surgical procedure, the implanted device and the bilateral             
STN stimulation were monitored and categorized as transient and permanent. Care was            
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 taken to distinguish between adverse events related to the progression of PD and the              
ones related to DBS. 
Data management and analysis 
The data were stored in Microsoft access databases using a custom input software that              
created the tables in the databases. The databases were then converted to            
comma-separated values (csv) using the open source software mdbtools         
(​https://github.com/brianb/mdbtools​). The data were then processed using the        
programming language python with the data analysis / scientific computing libraries:           
pandas, numpy, scipy, matplotlib, seaborn.  
The alpha was set to 0.05, and all the inferential tests were two-tailed. The significance               
levels of the statistical tests are shown using the asterisk notation: p< 0.05 : ​*​, p < 0.01:                  
**​, p<0.001: ​***​, no significance: ​ns​.  
The results are presented in an exploratory data analysis manner and further statistical             
tests were conducted when appropriate. All the observations were checked for normality            
and outliers were discarded. 
In the study the primary endpoint is the UPDRS III scores. The difference in UPDRS III                
as the years progress is asserted with three different treatments: 1) med “off”/stim “off”              
(as control), 2) med “on”/stim “off”, 3) med “off”/stim “on” and 4) med “on” / stim “on”                 
compared to the preoperative med “off” condition, that serves as a baseline. Med             
“off”/”on” describes treatment with/without levodopa equivalent medication respectively        
and stim “off”/”on” describes inactive/active bilateral STN stimulation respectively. 
Due to the dependency of the observations, paired t-tests were conducted up to 4 years               
after the surgery, always comparing with the baseline scores. Due to missing            
observations occurring at random for some years, only a subset of the patients was              
compared. These scores were collected by specialized physicians using structural          
neurological tests and are the most reliable results in the study.  
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 The tables presenting the results show the mean scores, that are calculated by taking              
the scores from all available patients at each year. The standard deviations are             
presented in brackets and the significance levels are also reported. 
The UPDRS III items were segmented into different groups and separate hypotheses            
were asserted, comparing the subscores for the four different treatments versus the            
subscores for the baseline. These subgroups are: a) Left/right/dominant. These are the            
particular items in the UPDRS III section that are side-specific. The dominant side is the               
left or right side that has the worst UPDRS III score, b) Gait, c) Tremor, d) Rigidity, e)                  
Akinesia. 
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 Results 
Demographic data 
The demographic data are summarized in Table 1. In this study, 94 patients were              
included. These individuals comprised patients that received the operation and had data            
for at least one of the post operative assessments between years 1 and 4 after the                
operation. The average age at surgery was 64.0 ± 8.0 years with a disease onset at                
48.9 ± 10.0 years (this average was calculated based on a subset of patients because               
of missing data). The disease duration, which is calculated as the number of years              
between the surgery and the year that the operation took place was 14.8 ± 6.1 years                
(again, this average is based on a subset of the patients because of missing data).  
The percentage of parkinson types in the patients are 38% equivalent, 38%            
akinetic/rigid and 24% tremor/dominant . Five patients out of the 94 passed away during              
the post operative assessment period for reasons not related to surgery or PD. 
 
Number of patients 94 
Age at surgery (years) 64.0 ± 8.0 
Disease onset (years) 48.9 ±  10.0  
Disease duration (years) 14.8 ± 6.1  
Parkinson type Equivalent (38%), akinetic/rigid (38%), tremor/dominant (24%) 
Gender Male: 55, Female: 39 
Levodopa equivalent dosage (mg) 950 ± 770 
Table 1. Summary of the demographic data. 
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 Stimulation parameters 
Table 2 summarizes the stimulation parameters of the STN. As shown in the table, the               
type of the stimulation was monopolar for the majority of the patients along all the 4                
post-op intervals after the operation. The stimulated contact is given in the table below.  
The mean value of the stimulation amplitude is given together with the standard             
deviation. In the study, the amplitude took values from 0.5 V to 7 V. 
 
Post-op Interval (years) 1 2 3 4 
Polarity Right (Monopolar, Bipolar) - 
occurrence  
84%, 16% 90%, 10% 82%, 18% 86%, 14% 
Polarity Left (Monopolar, Bipolar) - 
occurrence 
88%, 12% 91%, 9% 87%, 13% 86%, 14% 
Main contact Right - medianopear 2 2 2-3 2 
Main contact Left - median 2 2 2 2 
Stimulation amplitude Right (V) - 
mean, (sd) 
3.1 (1.2) 3.0 (1.2) 3.3 (1.3) 3.0 (1.4) 
Stimulation amplitude Left (V) - 
mean, (sd) 
3.3 (1.2) 3.1  (1.2) 3.4 (1.3) 3.2 (1.1) 
Stimulation frequency (Hz) - 
median (occurrence) 
130 (85%) 130 (82%) 130 (85%) 130 (86%) 
Pulse width Right (μs) - median 60 60 60 60 
Pulse width Left (μs) - median 60 60 60 60 
Table 2. Summary of the stimulation parameters for right and left electrodes.  
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 The stimulation frequency describes the frequency of the stimulation pulse, in Hz. The             
median value is noted (130 Hz), together with the occurrence percentage. Values            
spanned a range from 120 Hz to 180 Hz. A frequency of 130 Hz was used in more than                   
80% of the patients in all 4 post-op intervals that were studied. 
Finally the pulse width had median value 60μs for all the post-op intervals. 
Motor disability scores (UPDRS III) 
Total scores 
The UPDRS III scores were collected before brain operation (baseline), 1, 2, 3 and 4               
years after surgery. The results are summarized in the graphs below.  
 
Figure 7. Left: Evolution of UPRDS III scores with stim “on”/”off”, keeping the med “off”.               
Right: Evolution of UPRDS III scores with stim “on”/”off”, keeping med “on”. 
 
In Figure 7 (left), it is shown that with the treatment med “off”/stim “off”, the scores are                 
approximately constant over the follow up period of the 4 years. The treatment med              
“off”/stim “on” leads to a positive effect in the UPDRS III scores, as they drop down                
significantly. No data point is shown at baseline for med “off”/stim “on” or med “on”/stim               
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 “on” since at baseline, the patients did not have the electrodes implanted. Despite the              
standard baseline with med “off”, med “on” is also considered as a comparison. 
Figure 7 (right) displays that med “on”/stim “off”, the UPDRS III scores get increasingly              
worse over the period of 4 years, suggesting that with the medication only, one can not                
alleviate the motor symptoms. On the other hand with the treatment med “on”/stim “on”,              
the UPDRS III scores are kept low and approximately constant over the period of three               
years. At baseline, administration of medication only is enough to achieve alleviation of             
motor disability symptoms and the score at baseline is similar to the med “on”/stim “on”,               
treatment over the course of 4 years.  
 
Figure 8 Left: Evolution of UPRDS III scores with med “on”/ stim “off” and med “off”/stim                
off”. Right: Evolution of UPRDS III scores with med “on”/ stim “on” and med ”off”/stim               
“on”. 
 
Figure 8 displays the results in a different way, by keeping the stimulation in the “off” or                 
“on” condition and varying the medication condition. 
Figure 8 (left), shows med “off”/stim “off” and med “on”/stim “off”. One can see, in the                
same manner as before, that when the treatment is med “on”/stim “off”, the UPDRS III               
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 scores are initially low but get worse every additional year and at four years, they               
approach med “off”/stim “off” scores. On the other hand, as shown in Figure 8  
 Before 
surgery 
After surgery (years) 
 baseline 1  2  3  4  
Stimulation/ 
Medication 
 stim 
“off” 
stim 
“on” 
stim 
“off” 
stim 
“on” 
stim 
“off” 
stim 
“on” 
stim 
“off” 
stim 
“on” 
med “off” 46.1 (16.0) 45.1 
(15.4)  
27.0 
(12.2)  
51.7 
(20.3) 
29.7 
(13.2)  
49.3 
(17.3) 
30.0 
(15.8) 
55.5 
(16.8) 
34.7 
(12.9) 
Baseline comparison  -41%  -36%  -​35%  -25% 
Significance level over preop. 
med “off” 
 ***  ***  ***  ** 
Significance level over preop. 
med “on” 
 ns  ns  ns  ** 
med “on” 22.6 (10.7) 33.0 
(14.1)  
20.5 
(9.6) 
38.3 
(17.7) 
22.7 
(12.1) 
42.2 
(18.2) 
22.9 
(12.6) 
45.0 
(15.2) 
25.4 
(12.2) 
Baseline comparison  -56%  -51%  -50%   -45% 
Significance level over preop. 
med “off” 
*** *** *** *** * *** ns *** 
Significance level over preop. 
med “on” 
*** ns *** ns *** ns *** ns 
Table 3. ​Total UPDRS III scores. The baseline comparison is shown . The significance              
levels compared to preoperative med “off” and med “on” treatments are shown            
respectively for all the available treatments except the med “off”/stim “off” one. 
 
(right), keeping the stimulation in the “on” condition, the UPDRS III scores are             
significantly lower with the treatment being med “on”/stim “on” or med “off”/stim “on”, up              
to the 4th year. 
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 In Table 3, the mean UPDRS III scores in yearly intervals up to four years after the                 
surgery are shown. The mean scores and standard deviations (in brackets) are given             
for all four different treatments. There is a significant decrease in percentage UPDRS III              
scores for the treatment med “on”/stim “on” of 50% and 45% for the years 3 and 4                 
respectively, compared to the baseline. The improvement is also evident for the med             
“off”/stim “on” condition, which shows a percentage reduction of 35% and 25% for years              
3 and 4 respectively.  
The UPDRS III scores are compared to med “off” and med “on” treatments before              
surgery and the significance levels for both are shown. 
Compared to the preoperative med “off” treatment, there is a significant reduction in the              
UPDRS III scores (p < 0.001) with the med “on”/stim “on” treatment, up to 4 years after                 
surgery. The med “off”/stim “on” treatment also shows significant reduction in the mean             
scores up to 4 years after surgery. The significance of the tests is p<0.001 except in                
year 4, where the significance is lower (p<0.01). The med “on”/stim “off” treatment             
shows lower UPDRS III scores with significance p<0.001 at the 1st and 2nd year after               
surgery with the significance level in year 3 being p<0.05. In year 4, the mean score                
does not show a significant difference, indicating that treatment based only on            
medication does not have a long term positive effect in handling the motor symptoms of               
Parkinson’s disease. 
Compared to the preoperative med “on” treatment, which is very successful in the early              
stage of the disease but not long term, the same treatment is not effective after surgery,                
as it results in a significant (p<0.001) increase in the mean UPDRS III scores.              
Comparing the med “off”/stim “on” treatment with the preoperative med “on”, there is no              
change in the scores up to the 3rd year and a significant increase (p<0.01) in year 4.                 
The med “on/stim “on” treatment shows no change in the mean scores with respect to               
preoperative med “on”, indicating a successful relief of symptoms up to 4 years after the               
surgery. 
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 Right, Left, Dominant sides  
  Before After surgery (years) 
  baseline 1  2  3  4  
Side Stimulation/ 
Medication 
 stim 
“off” 
stim 
“on” 
stim 
“off” 
stim 
“on” 
stim 
“off” 
stim 
“on” 
stim 
“off” 
stim 
“on” 
Dominant med “off” 17.8 (6.1) 17.1 
(5.6)  
ns 
 
9.8 
(4.4) 
*** 
-45% 
19.4 
(7.6) 
ns 
10.3 
(4.8) 
*** 
-42% 
18.7 
(7.0) 
ns 
10.7 
(6.1) 
*** 
-40% 
20.7 
(7.2) 
ns 
11.5 
(4.2) 
*** 
-35% 
med “on” 9.0 (4.6) 12.8 
(5.9) 
*** 
 
7.7 
(3.9) 
*** 
-57% 
14.1 
(7.3) 
*** 
7.9 
(4.6) 
*** 
-56% 
16.4 
(7.6) 
* 
8.1 
(5.0) 
*** 
-55% 
16.7 
(6.4) 
ns 
7.8 
(4.0) 
*** 
-56% 
Right med “off” 15.5 (6.3) 15.3 
(6.0) 
ns 
8.5 
(3.6) 
*** 
-45% 
16.6 
(8.4) 
ns 
8.6 
(4.5) 
*** 
-45% 
16.0 
(6.5) 
ns 
9.2 
(6.6) 
*** 
-41% 
18.7 
(6.7) 
ns 
9.4 
(4.0)  
*** 
-39% 
med “on” 7.6 (4.3) 10.5 
(5.5)  
*** 
6.0 
(2.9) 
*** 
-61% 
12.9 
(6.9) 
*** 
6.6 
(4.0) 
*** 
-57% 
13.8 
(7.8) 
ns 
6.9 
(4.7) 
*** 
-55% 
14.5 
(6.5) 
ns 
6.4 
(3.8) 
*** 
-59% 
Left med “off” 15.5 (6.9) 14.4 
(5.8)  
ns 
8.7 
(4.7)  
*** 
-44% 
17.3 
(7.4) 
ns 
9.4 
(5.1) 
*** 
-39% 
16.3 
(6.9)  
ns 
9.3 
(5.5) 
*** 
-40% 
17.7 
(7.7) 
ns 
10.6 
(4.7) 
** 
-32% 
med “on” 7.6 (4.7) 11.5 
(6.1)  
*** 
7.0 
(4.2) 
*** 
-55% 
12.4 
(7.0)  
*** 
7.2 
(4.8) 
*** 
-54% 
14.1 
(7.4)  
ns 
7.3 
(4.3)  
*** 
-53% 
14.0 
(6.7)  
ns 
7.1 
(4.1) 
*** 
-54% 
Table 4. Subscores for “dominant”, “right” and “left” sides. Baseline comparison and            
significance  levels are shown. 
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A breakdown of the UPDRS III subscores concerned with the different sides (left, right)              
together with the dominant side of the disease (that is the side affected mostly by the                
disease) is shown in Table 4.  
In this case, the subscores are compared only to the preoperative med “off” condition.              
The observations follow the ones of total UPDRS III subscores, that show that             
administering only medication does not relieve the Parkinson’s disease symptoms after           
the 2nd year. In year 3, the med “on”/stim “on” treatment shows a 55% decrease on                
both the dominant and right side and 53% decrease on the left side. In year 4, the med                  
“on”/stim “on” treatment shows a similar decrease in the UPDRS III subscores, with the              
56%, 59% and 54% decreases on the dominant, right and left sides respectively. Med              
“off”/stim “on” treatment also shows a significant improvement in the UPDRS III            
subscores, with a reduction of 40% and 35% for the dominant side for years 3 and 4                 
respectively, 41% and 39% for the right side for years 3 and 4 respectively and 40%                
and 32% for the left side for years 3 and 4 respectively. 
Gait, Rigidity, Tremor, Akinesia 
The tremor subgroup (Figure 9) contains the UPDRS items associated with action and             
resting tremor. Tremor shows the highest percentage decrease compared to the other            
subgroups, with a 57% decrease in year 3 and 67% decrease in year 4 of the treatment                 
med “on”/stim “on” over the baseline. Treatment med “off”/stim “on” also shows a large              
decrease: 48% in year 3 and 43% in year 4.  
The gait subgroup (Figure 10) contains the following items: “arise from chair”, posture,             
postural stability, gait and body bradykinesia. The gait scores decrease by 43 % and              
21% for the years 3 and 4 respectively for the med “on”/stim “on” treatment and 28%                
and 1% (not significant decrease) for years 3 and 4 respectively for the med “off”/stim               
“on” treatment. Evidently, med “off”/stim “on” treatment provides substantially lower          
percentage decrease for this particular subgroup, with no significant decrease at four            
years. 
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 The akinesia subscores (Figure 11) show 45% percentage decrease for year 3 and 40%              
for year 4, for the med “on”/stim “on” treatment, over the baseline. The med “off”/stim               
“on” treatment shows lower percentage decrease, 35% in year 3 and 20% for year 4               
over the baseline.  
The rigidity scores (Figure 12) show 45% and 50% percentage decrease for years 3              
and 4 respectively, for treatment med “on”/stim “on”. The treatment med “off”/stim “on”             
results in 22% (not significant decrease) and 34% percentage decrease for years 3 and              
4 respectively. The percentage decrease in year 3 for med “on”/stim “off” is not              
significant, in contrast to the scores for years 1, 2 and 4 for the same treatment. 
 
  Before 
surgery 
After surgery (years) 
  baseline 1  2  3  4  
UPDRS III 
subgroup 
Stimulation/ 
Medication 
 stim 
“off” 
stim 
“on” 
stim 
“off” 
stim 
“on” 
stim 
“off” 
stim 
“on” 
stim 
“off” 
stim 
“on” 
Tremor med “off” 8.8 (6.2) 8.3 (5.6)  
ns 
4.2 
(2.8)  
*** 
-52% 
10.0 
(6.1)  
ns 
4.1 
(3.1)  
*** 
-53% 
8.6 
(6.0)  
ns 
4.6 
(4.3) 
*** 
-48% 
9.5 
(5.5) 
ns 
5.0 
(2.3)  
* 
-43% 
med “on” 4.7 (4.0) 6.2 (5.3)  
*** 
3.0 
(1.8) 
*** 
-66% 
7.0 
(5.5)  
* 
-65% 
3.1 
(2.7) 
*** 
8.4 
(5.4)  
ns 
3.8 
(2.8) 
*** 
-57% 
6.8 
(4.9) 
ns 
2.9 
(1.6)  
* 
-67% 
Gait med “off” 10.0 (4.3) 10.5 (4.6) 
ns 
7.0 
(4.1) 
*** 
-30% 
11.2 
(5.5) 
ns 
7.5 
(4.4) 
*** 
-25% 
10.8 
(5.3) 
ns 
7.2 
(4.0) 
** 
-28% 
12.4 
(4.0) 
ns 
9.9 
(4.7) 
ns 
-1% 
med “on” 4.9 (2.6) 7.5 (3.8)  
*** 
5.5 
(3.0)  
*** 
-45% 
8.6 
(4.9)  
** 
5.8 
(3.9) 
*** 
-42% 
8.4 
(4.7) 
* 
5.7 
(3.8) 
*** 
-43% 
10.9 
(4.4) 
ns 
7.9 
(4.0) 
** 
-21% 
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 (Table 5 continued) Before 
surgery 
After surgery (years) 
  baseline 1  2  3  4  
UPDRS III 
subgroup 
Stimulation/ 
Medication 
 stim 
“off” 
stim 
“on” 
stim 
“off” 
stim 
“on” 
stim 
“off” 
stim 
“on” 
stim 
“off” 
stim 
“on” 
Akinesia med “off” 16.6 (6.5) 16.4 (6.4) 
ns 
10.4 
(5.2) 
*** 
-37% 
18.9 
(7.2) 
ns 
 
11.4 
(5.9) 
*** 
-31% 
16.6 
(6.5) 
ns 
10.8 
(7.3) 
** 
-35% 
20.0 
(7.3) 
ns 
13.2 
(6.4) 
* 
-20% 
med “on” 8.8 (4.7) 13.0 (5.7) 
*** 
8.5 
(4.5) 
*** 
-49% 
14.8 
(7.6) 
* 
9.0 
(5.3) 
*** 
-46% 
15.8 
(7.3) 
ns 
9.2 
(5.9) 
*** 
-45% 
16.6 
(7.6) 
ns 
9.9 
(6.2) 
*** 
-40% 
Rigidity med “off” 8.8 (4.3) 8.3 (3.4) 
 ns 
 
5.2 
(3.0) 
*** 
-41% 
9.7 
(4.5) 
ns 
5.5 
(3.3) 
*** 
-38% 
10.3 
(3.8) 
ns 
6.8 
(4.2)  
ns 
-22% 
11.1 
(4.2) 
*  
5.8 
(3.4) 
* 
-34% 
med “on” 4.5 (3.0) 6.0 (3.2)  
*** 
4.2 
(2.4)  
*** 
-52% 
6.8 
(4.3)  
** 
4.6 
(3.7)  
*** 
-48% 
8.2 
(3.8)  
ns 
4.8 
(3.0) 
*** 
-45% 
8.3 
(4.0) 
ns 
4.4 
(2.4) 
*** 
-50% 
Table 5. UPDRS III subscores for groups: Tremor, Gait, Akinesia, Rigidity. The            
subscores are shown up to 4 years after the operation. The percentage decrease of the               
med “on”/stim “on” compared to the preoperative med “off” are shown. 
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Figures 9-12. UPDRS III symptom specific groups. Figure 9 (top left): Tremor. Figure 10              
(top right) Gait. Figure 11 (bottom left): Akinesia. Figure 12 (bottom right): Rigidity. 
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 Medication related complications (UPDRS IV) 
 
 
Figure 13. Medication related complications (UPDRS IV) scores. 
 
 Before 
surgery 
After surgery (years) 
 baseline 1 2 3 4 
UPDRS IV score 8.0 (4.0) 4.9 (3.8)  
* 
-39% 
4.9 (3.5)  
* 
-39% 
4.6 (4.0) 
 ** 
-43% 
5.3 (4.2)  
* 
-34% 
Table 6. Medication related complications (UPDRS IV scores) for 4 years after brain             
surgery. 
 
The summary of the UPDRS IV scores (Figure 13, Table 6), that describe the              
complications introduced due to levodopa (baseline) and levodopa in conjunction with           
DBS for 1, 2, 3 and 4 years afters surgery show an abrupt decrease, with a p-value <                  
0.05 at year 1, 2 and 4 and p-value < 0.01 at year 3. The scores after the 1st year are                     
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 compared with the scores at baseline (only levodopa). The substantial decrease of the             
related complications (43% in 3rd year and 34% in 4th year) are very beneficial for the                
quality of life of each patient.  
Motor activities of daily living (UPDRS II) 
 
Figure 14. Sum of UPDRS II scores for med “on”/stim “on” and med “off”/stim “on”. At                
baseline (year 0), the scores shown are for med “off” and med “on” conditions. 
  
Table 7 summarizes the motor activities of daily living, as reported by the patients and               
depicted graphically in Figure 14. The stimulation state is “on” for all the years following               
brain surgery and the treatment is compared to baseline (in this case stimulation is “off”               
as the DBS system has not been implanted yet. Years 3 and 4 show a drop in the                  
scores of 39% and 25% (not significant result, however the sample size at this point               
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 was very small, so the result is not reliable), when compared to the baseline med “off”                
condition. 
 Before surgery After surgery/stim ”on” (years) 
Medication 
condition 
baseline 1 2 3 4 
med“off”  22.3 (8.9) 18.6 (8.5) 
 * 
-17% 
20.7 (7.7)  
* 
-7% 
19.2 (8.3) 
 * 
-14% 
26.7 (8.3)  
ns 
+20% 
med “on”  12.9 (5.9) *** 11.6 (6.5) 
 *** 
-48% 
13.8(6.1)  
*** 
-38% 
13.6 (5.6)  
*** 
-39% 
16.7 (7.2)  
ns 
-25% 
Table 7. The motor activities of daily life (UPDRS II) scores, with med“off” and med “on”.                
The stimulation is always in the “on” state and the baseline treatment is med “off”. 
Non-motor activities of daily living (UPDRS I) 
 
Figure 15. Left: Shows the sum of UPDRS I scores up to the 4th year after operation.  
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 Before surgery  After surgery (years) 
 baseline 1 2 3 4 
UPDRS I score 2.9 (1.9) 2.8 (1.6) 
ns 
-3% 
3.3 (2.0) 
ns 
+14% 
3.3 (2.0)  
ns 
+14% 
3.7 (2.7)  
ns 
+28% 
Table 8. UPDRS I scores. 
 
Figure 15 above shows the scores for the items in the UPDRS 1 part of the UPDRS                 
scale, that includes: mentation, thought disorder, depression, motivation/initiative.  
Table 8 shows that there is no significance increase in the UPDRS 1 scores, indicating               
that during the follow-up period of four years after surgery, there is not a further               
significant impairment in the non-motor activities of the daily living. The table shows an              
increase of 14% and 28% for 3rd and 4th years after surgery respectively, however the               
increase is not significant. 
Levodopa equivalent intake 
  
Figure 16. Left: Levodopa equivalent dosage up to the 4th year after operation. Right:              
Levodopa equivalent number of distinct dosage up to the 4th year after operation. 
  
49 
  
 Before 
surgery 
After surgery (years) 
 baseline 1 2 3 4 
Levodopa 
equivalent dosage 
(mg) 
950 (770) 540 (250)  
*** 
-43% 
570 (280)  
*** 
-40% 
570 (250)  
**  
-40% 
640 (270)  
* 
-33% 
Dose count 6.2 (1.6) 5.5 (1.6)  
* 
-11% 
5.2 (1.8) 
 *** 
-16% 
4.9 (1.6) 
 *** 
-21% 
5.1 (1.4) 
 * 
-18% 
Table 9. Levodopa equivalent dosage and dose count. 
 
Figure 16 and Table 9 show the levodopa equivalent dosages (see methodology for             
explanation). Compared to before surgery, the levodopa equivalent dosages is shown to            
significantly drop (significance levels are p<0.001 for years 1 and 2, p< 0.01 for year 3                
and p<0.05 for year 4). As it is shown in the figure there is a highly pronounced transient                  
drop observed on the 1st year after surgery, with a slight, not significant increase              
(compared to year 1) after that. The average percentage decreases of Levodopa            
equivalent dosages over the baseline are 40% in the 3rd year and 33% in the 4th year.  
The dosage count shows a significant decrease compared to before surgery as well.             
The significance levels are p<0.05 for years 1 and 4, p<0.001 for year 2 and p<0.01 for                 
year 3. The percentage decrease compared to the baseline is 21% and 18% for years 3                
and 4 respectively. 
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 Hoehn and Yahr staging scale (UPDRS V) 
 
Figure 17. Hoehn and Yahr staging scale (UPDRS V) 
 Before surgery After surgery (years) 
 baseline 1 2 3 4 
UPDRS V score 3.6 (0.8) 3.3 (0.8)  
*** 
3.4 (0.7)  
*** 
3.6 (0.6)  
ns 
3.9 (0.8)  
ns 
Table 10. UPDRS 5 scores.  
 
The UPDRS 5 scores (Figure 17, Table 10) are in the range of 3 to 4 over the 4 years                    
after surgery. The scores represent ​mild to moderate parkinson’s disease, some           
postural instability, physically independent to ​severe disability, still able to walk or stand             
unassisted respectively. The scores are significantly lower in year 1 and 2 and then they               
show no significant change in year 3 and 4 over the baseline 
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 MMSE and BDI scores 
  
 
Figure 18. Left: Mini-mental state examination scale, showing no significance difference           
in the scores within the follow up period. Right: Beck depression inventory scale,             
showing no significance difference in the scores within the follow up period. 
 
The results for the MMSE do not show a significant change in year 1 compared to the                 
baseline, then they show a decrease for years 2 and 3 (p<0.05) and a more significant                
decrease in year 4 (p<0.01). 
Scores below 23 indicate cognitive impairment. As it is shown in Figure 18 (left) above,               
the mean score in years 2 and 3 after operation is at ~27 points, with a standard                 
deviation of ~3 points, indicating a score of 24 at one standard deviation away from the                
mean (in the negative direction). Hence, even though the t-test shows a decrease in the               
2nd and 3rd compared to pre-operation, this decrease in the MMSE score is not              
translated to a serious cognitive impairment. However, for the 4th year after the             
operation the decrease is higher, with a mean score of 25 and a standard deviation of                
5.This indicates that some cognitive impairment is evident in year 4  after surgery.  
No significant change in the BDI is observed when compared to baseline (Figure 18              
left). Scores in the range 0 to 13 points indicate minimal depression and scores in the                
range of 14 to 19 indicate mild depression. The score before operation is at a 9.5 ± 5.5.                  
Thus the mean score falls well in the region of minimal depression, and that is carried                
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 forward unchanged up to 4 years after operation as far as the paired t-test is concerned.                
A higher increase in the mean score occurs in the 4th year, with the mean score being                 
at the boundary of minimal/mild depression, but the majority of the patients would fall in               
the minimal/mild depression region, as scores in the range of 20-28 (moderate            
depression) or 29 - 63 (severe depression) are far away from the range of values               
observed.  
Dysphagia, Dysarthria 
  
Figure 19. Dysphagia (left) and dysarthria (right) scores for the 4 year follow up after               
surgery. 
 
The dysphagia and dysarthria scores (Figure 19) have been transformed from           
categorical to numerical in order to facilitate the scoring. None, mild, moderate and             
severe dysphagia categories have been assigned the numerical scores 0, 1, 2, 3             
respectively. 
For dysphagia, there is no significant change compared to the baseline for 1, 2 years,               
there is an increase (p<0.05) at year 3 and a more significant increase at year 4                
(p<0.01). The baseline dysphagia mean score is at 0.6 indicating a none to mild              
dysphagia. In year 3, the mean score increases to 1.1, that translates to predominantly              
mild dysphagia. In year 4, the mean score increases again to 1.4, which falls in the                
mild/moderate category.  
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 Dysarthria scores have the following progress: in year 1 the increase has significance             
p<0.05, for year 2 p<0.001, for year 3, p<0.01 and for year, p<0.001. The baseline               
preoperative dysarthria score is at 0.5 indicating none/mild dysarthria induced          
symptoms, 1 at year 1, indicating mild dysarthria, 1.3, 1.4, and 1.7 in years 2, 3 and 4                  
respectively, indicating mild/moderate dysarthria.  
Adverse events 
The adverse events related to the surgical procedure, the implanted device and the             
bilateral STN stimulation are summarized in Table 11. 
Most of the adverse events related to the surgical procedure were not serious, except              
intracerebral hemorrhage with persistent disability that is reported in 3 patients.           
Intracerebral hemorrhage was additionally observed in 2 patients, but with no persistent            
disability. Ischemic stroke was observed in 1 patient. Nine patients experienced a            
transient postoperative delirium. Common complications that may occur in any surgical           
procedure and narcosis, such as pulmonary artery embolism and vocal cord dysfunction            
were observed in 1 patient for each complication. Subdural hematoma was observed in             
1 patient. One patient had symptomatic bleeding detected in MRI. Wound healing            
problems caused a transient complication in 1 patient and a permanent complication in             
1 patient. Electrodes were repositioned in 4 patients in total, in 2 patients due to               
misplacement and in 2 patients due to dislocation. The stimulation generator had to be              
replaced in 1 patient due to infection.  
Permanent eyelid-opening apraxia, a common adverse effect of DBS, was observed in            
5 patients. Moderate psychiatric adverse events, such as psychosis, hypomania,          
apathy, and impulsive aggressive behavior were observed in a very small number of             
patients, as shown in Table 11. Finally, weight gain was reported in 1 patient. 
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 Type of adverse event Transient Permanent 
Related to surgery and device 
Intracerebral hemorrhage 2 3 
Ischemic stroke  1 
Asymptomatic bleeding detected on MRI 1  
Delirium 9  
Pulmonary embolism 1  
Vocal cord dysfunction 1  
Subdural hematoma 1  
Wound healing problem 1 1 
Electrode misplacement 2  
Electrode dislocation 2  
Infection of the stimulator 1  
Related to STN stimulation 
Eyelid-opening apraxia  5 
Psychosis 2  
Hypomania 2 1 
Impulsive aggressive behavior 1 1 
Weight gain  1 
Apathy 4 3 
Table 11. Adverse events related to surgery, device or STN stimulation. 
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 Discussion 
The main result of this study shows that bilateral DBS of STN provides long term               
improvement of UPDRS III scores in patients with advanced Parkinson’s disease in both             
medication “off” and “on”. 
The overall UPDRS III during neurostimulation markedly improved with and without           
medication, with the improvements over baseline sustained for the entire follow-up           
period of 4 years after surgery. When comparing UPDRS III score during            
neurostimulation with medication, to the preoperative med “on” condition, no significant           
change was observed, meaning that treatment with neurostimulation in conjunction with           
medication remained quite stable over the 4 years of follow-up. On the contrary med              
“on”/stim “off” treatment gave continuously worse scores compared to the preoperative           
med “on”. This underlines the importance of bilateral DBS, as the medication alone             
could not provide a sustained improvement in the UPDRS III scores. 
The improvement in the UPDRS III subscores related to the body sides (left, right,              
dominant) is evident with a significant decrease in the scores for med “off”/stim “on” and               
med “on”/stim “on” over baseline. The fact that there is a remarkable reduction on the               
side affected most dominantly by PD is highly important for the quality of life of the                
parkinsonian patients. 
Furthermore, for all UPDRS III symptom-specific subscores: gait, rigidity, akinesia and           
tremor, a significant improvement was observed.  
Resting and action tremors can be significantly benefited from bilateral DBS in the STN,              
with the results showing the highest decrease compared to the other UPDRS III             
symptom-specific subscores. As tremor is a very disabling motor symptom of PD,            
reducing the quality of life of an individual in several ways, its effective alleviation using               
bilateral STN DBS with or without medication is a very important relief in an individual’s               
quality of life. 
Gait subscores show that it is important to use medication together with DBS for the               
alleviation of gait related parkinsonian symptoms, since the decrease in the gait            
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 subscore is much higher with the med “on”/stim “on” treatment compared to med             
“off”/stim “on”. In the 4th year, the gait subscore in med “off”/stim “on” returns to the                
preoperative values.The worsening of the gait disorders is consistent with the the            
finding that symptoms such as gait disorder, postural instability and dysarthria are in a              
category of symptoms which respond less well to levodopa treatment [bonnet1987] and            
result from increasing severity of cerebral non-dopaminergic lesions [agid1991].  
Akinesia and rigidity UPDRS III subscores with med “on”/stim “on” and med “off”/stim             
“on” show a sustained improvement up to 4 years after surgery, compared to baseline. 
A significant decrease in UPDRS IV is observed. This is most likely due to the reduction                
of the levodopa equivalent dosage administered to the patients. The dyskinesia-related           
pain and disability together with off-periods related with levodopa medication are critical            
factors affecting a patient’s everyday life, and the reduction of such complications is a              
major advantage in the patients’ quality of life. Thus, it is evident that the stimulation of                
STN makes possible a substantial reduction  in the dose of dopaminergic treatment. 
Motor activities of daily living (UPDRS II) show a marked decrease when compared to              
baseline, a result consistent with the improvement shown in UPDRS III scores.  
Both levodopa equivalent dosage and the number of single levodopa doses were            
significantly decreased. Reducing the daily levodopa dosages is beneficial due to the            
reduction of the medication related side effects. The reduction of the number of single              
daily dosages is also beneficial for the comfort of the individuals. 
Non-motor activities of daily living (UPDRS I: Mentation, behavior and mood) show no             
significant change compared to the baseline.  
Hoehn and Yahr staging scale shows a transient decrease in the PD state in the 1st and                 
2nd year of the follow up, followed by a return to the preoperative values in the 3rd and                  
4th year, indicating that the measure of the PD stage shows in essence no change by                
the end of the follow-up period, compared to baseline. 
The MMSE scores remain in the preoperative values up to the 3rd year after surgery               
and decline in the 4th. Despite the decline in the 4th year, the mean MMSE score                
indicates a normal pre- and post - operative cognition. 
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 The BDI scores remain in the preoperative values up to the 4th year of the follow up,                 
indicating that depression does not worsen. However, the mean score up to the 3rd              
follow up year indicates minimal depression and in the 4th year the mean score falls at                
the boundary of minimal/mild depression. The tendency towards worsening of          
depression is common as PD progresses [marsh2013]. 
Dysphagia score in year 3 and 4 after operation is at the mild and mild/moderate               
categories respectively, thus, dysphagia is developed in the patients in this study. The             
fact that development of dysphagia occurs after the 3rd year suggests that it is a               
complication not clearly linked to neurostimulation, as dysphagia is commonly observed           
during the progression of PD. Dysphagia causes major reduction in the quality of life of               
individuals and it is observed in 80% of patients with PD, with difficulty in swallowing               
being the most affecting problem caused by PD. The swallowing impairment causes            
complications in the medication intake, malnutrition and can lead to aspiration           
pneumonia, that is one of the major cause of death in PD. In order to make the quality                  
of life of the patients better, early identification and management of swallowing            
abnormalities is crucial for minimizing the likelihood of the complications that can impact             
the life of the patients in a negative manner. 
For dysarthria, there are significant increases in the mean scores starting in year 1,              
compared to the baseline. This is consistent with literature findings, indicating that            
dysarthria precedes dysphagia [tjaden2008]. It also suggests there might be a stronger            
link between the development of dysarthria and neurostimulation, though dysarthria is           
also common as PD progresses. Reduced comprehensibility is considered the most           
significant functional limitation of dysarthria which affects 90% of patients with PD.            
However, a person’s ability to communicate in a way that is considered normal can be               
affected due to voice and speaking rate, also affected by dysarthria. 
Adverse events related to surgical procedure, device and stimulation were observed,           
similarly to data from other groups. These effects were carefully monitored in order to              
distinguish the ones that were related to the stimulation with the ones that are common               
adverse events of PD. These adverse events might have an impact in the activities of               
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 daily living, thus the quality of life of the individual patients, however, the number of               
patients that experienced serious adverse events was very small. Three percent of the             
patients experienced serious permanent disability due to brain hemorrhage during          
surgery, a result in line with other studies [beric2001, buhmann2007,          
kleinerfisman2006]. Moderate transient adverse events, such as delirium, psychosis,         
aggressive impulsive disorder, hypomania or apathy were not frequent. Eyelid-opening          
apraxia [krack2005], which is very common in STN stimulation [kleinerfisman2006] was           
more frequent (5 patients) but still very low compared to the total number of patients               
(94) in the cohort. Weight gain is frequently reported in the literature [barichella2003,             
krack2005], but was not common in this study. 
In conclusion, this study demonstrates the efficacy of bilateral STN stimulation in            
patients with advanced PD. The results are aligned with previous studies of patients             
treated with bilateral STN stimulation [schüpback2005, krack2003, deuschl2006].        
Moreover, the safety of the treatment, which was assessed by carefully monitoring the             
adverse events, was in the acceptable range, similar to results from other studies             
[beric2001, buhmann2007, kleinerfisman2006].  
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 Summary 
Ninetyfour patients with advanced Parkinson’s disease were assessed retrospectively         
one, two, three and four years after bilateral surgery for Deep Brain Stimulation of the               
subthalamic nucleus. The patients were treated with bilateral subthalamic nucleus          
stimulation and assessed under different conditions with levodopa (“medication on”) and           
without levodopa (“medication off”) with use of the Unified Parkinson’s Disease Rating            
Scale and were compared with the preoperative “medication off” condition. In addition,            
the symptoms depression, cognition, dysphagia and dysarthria were monitored during          
the follow-up period. One year after surgery, the motor disability scores showed a             
neurostimulation induced improvement of 56% and 41% in the “medication on” and            
“medication off” conditions respectively. Four years after surgery, accompanied with the           
progression of Parkinson’s disease, the improvement was at 45% and 25% in the             
“medication on” and “medication off” conditions respectively. The neurostimulation         
induced improvement was 57% and 45% over baseline at one year after surgery on the               
body side dominantly affected by Parkinson’s disease in the “medication on” and            
“medication off” conditions respectively. At four years, the improvement was sustained           
at 56% in “medication on” and slightly reduced to 35% in “medication off”. Symptoms              
tremor, akinesia and rigidity showed a markedly sustained improvement in “medication           
on” condition, with the improvement at four year being 57%, 40% and 50% respectively.              
The improvement was at 43%, 20% and 34% in “medication off” condition. Gait showed              
a sustained improvement only up to three years (43% at year 3) in “medication on”               
condition, with the improvement in “medication off” being 28% at three years. The             
medication related complications were markedly improved, with the improvement at one           
year being 39% and at four years being 34%. The motor activities of daily life showed a                 
significant improvement of 39% and 14% in “medication on” and “medication off”            
conditions respectively up to three years after surgery. Levodopa dosage was           
drastically decreased by 33% at four years. Depression scores did not worsen during             
the follow-up period. Cognitive performance showed slight but significant decline in the            
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 fourth year. Mean scores for dysphagia and dysarthria increased at four years after             
surgery.  
Persistent adverse events related to the brain surgery were observed in 3% of the              
patients. A few patients experienced eyelid-opening apraxia. 
In conclusion, this study demonstrates the efficacy of bilateral stimulation of the            
subthalamic nucleus in patients with advanced Parkinson’s disease. The results are           
aligned with previous studies. Moreover, the safety of the treatment, which was            
assessed by carefully monitoring the adverse events, was in the acceptable range,            
similar to results from other studies. 
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 Zusammenfassung 
Vierundneunzig Patienten mit fortgeschrittener Parkinson-Krankheit wurden retrospektiv       
jeweils ein, zwei, drei und vier Jahre nach einer bilateralen tiefen           
Hirnstimulations-Operation des Nucleus subthalamicus untersucht. Die Patienten       
wurden unter der bilateralen Nucleus subthalamicus Stimulation mit Levodopa         
(“medication on”) und ohne Levodopa (“medication off”) unter Verwendung der Unified           
Parkinson’s Disease Rating Skala bewertet und mit dem präoperativen “medication off”           
Zustand verglichen. Zudem wurden während der Nachbeobachtungszeit Symptome        
einer Depression, Kognition, Dysphagie und Dysarthrie überwacht. Ein Jahr nach der           
Operation zeigte die motorische Einschränkung eine durch die        
Neurostimulation-induzierte Verbesserung von 56% unter “medication on” und 41%         
unter “medication off” gegenüber dem Ausgangswert. Vier Jahre nach der Operation lag            
die Verbesserung der motorischen Einschränkung, mit dem Fortschreiten der         
Parkinson-Krankheit, bei 45% bzw. 25% unter “medication on” bzw. “medication off ”.            
Auf der von der Erkrankung stärker betroffenen Seite betrug die Verbesserung ein Jahr             
nach der Operation auf 57% unter “medication on” und 45% unter “medication off”. Im              
vierten Jahr nach der Operation konnte eine annähernd gleichbleibende Verbesserung          
von 56% unter “medication on” verzeichnet werden sowie eine Reduktion auf 35% unter             
“medication off”. Die Symptome Tremor, Akinesie und Rigor zeigten eine auch noch im             
4. Jahr deutlich anhaltende Verbesserung von 57% (Tremor), 40% (Akinesie), 50%           
(Rigor) unter “medication on” respektive von 43%, 20% bzw. 34% unter “medication off”.             
Das Gangbild zeigte nur bis zum dritten Jahr (43% im dritten Jahr) eine dauerhafte              
Verbesserung unter “medication on” wobei eine Verbesserung unter “medication off” auf           
28% gesehen wurde. Komplikationen im Zusammenhang mit der Medikation wurden          
deutlich reduziert, wobei die Verbesserung nach einem Jahr bei 39% und im vierten             
Jahr bei 34% lag. Die motorischen Aktivitäten des täglichen Lebens zeigten bis zu drei              
Jahre nach der Operation eine signifikante Verbesserung von 39% bzw. 19% unter            
“medication on” bzw. “medication off”. Die benötigte Levodopa-Dosis sank nach vier           
Jahren drastisch um 33%. Der mittlere Depressionswert blieb während des gesamten           
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 Beobachtungszeitraumes unverändert. Die kognitive Leistung war bis zum dritten Jahr          
unverändert, im vierten Jahr jedoch verschlechterte sie sich. Die mittleren Werte für            
Dysphagie und Dysarthrie stiegen vier Jahre nach der Operation an.  
Anhaltende Nebenwirkungen im Zusammenhang mit der Gehirnoperation wurden bei         
3% der Patienten beobachtet. Einige Patienten erlitten eine Augenlid-Öffnungs-Apraxie. 
Zusammenfassend belegt diese Studie die Wirksamkeit der bilateralen Stimulation des          
Nucleus subthalamicus bei Patienten mit fortgeschrittener Parkinson-Krankheit. Die        
Ergebnisse stimmen mit ähnlichen Studien überein. Darüber hinaus lag die Sicherheit           
der Therapieform, die durch sorgfältige Überwachung der Nebenwirkungen beurteilt         
wurde, im akzeptablen Bereich, welches den Ergebnissen anderer Studien entspricht. 
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